gps’ decisions on drug therapies by number needed to treat
DESCRIPTION
GPs’ decisions on drug therapies by number needed to treat. Peder A. Halvorsen University of Tromsø, Norway Torbjørn Wisløff Ivar Sønbø Kristiansen University of Oslo, Norway. Mr Smith. - Mr Smith (55) consults you for a check up on blood pressure and cholesterol because his - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/1.jpg)
GPs’ decisions on drug therapies
by number needed to treat
Peder A. HalvorsenUniversity of Tromsø, Norway
Torbjørn WisløffIvar Sønbø Kristiansen
University of Oslo, Norway
![Page 2: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/2.jpg)
Mr Smith
- Mr Smith (55) consults you for a check up on
blood pressure and cholesterol because his
father got a heart attack at age 52.
- Mr Smith has no symptoms
![Page 3: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/3.jpg)
Workup of the Mr Smith case
Glucose 4.3
EKG Normal
BMI
Hip waist ratio
Physical fitness
24.5
1.1
Above
average
Smoking No
Blood pressure 156/98
Total cholesterol
LDL
HDL
Triglycerides
8.1
6.1
1.1
2.0
Ten year risk of CVD: 20 out of 100
Ten year risk of death due to CVD: 8 out of 100
![Page 4: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/4.jpg)
Neostatin
• A new cholesterol lowering drug therapy
• Randomized trials in primary care as well as hospitals.
• Side effects similar to other statins
• Cost per year: 1000 NOK
![Page 5: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/5.jpg)
Neostatin
• If groups of 19 people takes Neostatin for 20 years, one
will observe 1 less patient with cardiovascular disease
compared to no therapy.
• Mr Smith has no clear preference for or against the drug
and asks for your opinion.
• Would you recommend Neostatin for Mr Smith?
![Page 6: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/6.jpg)
NNT
• NNT=1/ARR (absolute risk reduction)
• ”The number of individuals that must be treated
to prevent one adverse outcome”
• “Intuitively meaningful and easy to understand”
![Page 7: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/7.jpg)
Lay people are rather insensitive to NNTs:
NNT Yes
50 76%
100 71%
200 70%
400 71%
800 68%
1600 67%
NNT patients must be treated for
three years to prevent one adverse
outcome.
Would you chose to take such a
drug?
Halvorsen PA, Kristiansen IS. Archives of Internal Medicine 2005
![Page 8: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/8.jpg)
Research questions
• Are GPs sensitive to the magnitude of
NNT when considering statin therapy?
• Do GPs use NNT when explaining risk
reductions to patients?
![Page 9: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/9.jpg)
Methods
• Subjects: 450 GPs in Norway
• Postal questionnaire survey
• Random allocation to three different
versions of the Mr Smith case
![Page 10: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/10.jpg)
Effect measures in the Mr Smith vignette
NNT after 20 years of therapy*---------------------------------------------------------------------------------------------------
Group 1 9
Group 2 19 (simvastatin)
Group 3 37
---------------------------------------------------------------------------------------------------
* Based on the NORCAD model of CVD disease in Norway
![Page 11: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/11.jpg)
Would you recommend Neostatin for Mr Smith?
□ Certainly “Yes”
□ Probably
□ Probably not “No”
□ Certainly not
![Page 12: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/12.jpg)
Rating scale: Is Neostatin good or bad?
What is your judgement of Neostatin as a prophylactic drug
against cardiovascular disease?
A very poor
choice0 1 2 3 4 5 6 7 8 9 10 A very good
choice
![Page 13: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/13.jpg)
Results
NNT Proportion recommending
Neostatin
n = 214
Mean score
rating scale
n = 203
10
19
37
![Page 14: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/14.jpg)
Results
NNT Proportion recommending
Neostatin
n = 214
Mean score
rating scale
n = 203
10 80%
19 74%
37 66%
Chi-square trend = 3.85
p = 0.05
![Page 15: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/15.jpg)
Results
NNT Andel som ville anbefale Neostatin
n = 214
Mean score
rating scale
n = 203
10 80% 6.0
19 74% 5.6
37 66% 4.8
Chi-square trend = 3.9
p = 0.05
ANOVA trend, F = 8.2
p = 0.005
![Page 16: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/16.jpg)
Explaining risk reductions to patients
How do you usually inform your patients about risk
reducing drug therapies?
□ In numerical terms
□ In qualitative terms
□ Both
□ None of these/not applicable in my work
![Page 17: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/17.jpg)
Results
• Qualitative terms only: 66 %
• Relative risk reduction: 21 %
• Absolute risk reduction: 24 %
• NNT 20 %
![Page 18: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/18.jpg)
Conclusion
• GPs were sensitive to the magnitude of NNT
when considering a new lipid lowering drug
• A minority of GPs would use NNT when
explaining risk reductions to patients.
![Page 19: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/19.jpg)
Acknowledgments
Torbjørn WisløffHenrik Støvring
Ivar Sønbø KristiansenOdense Risk Group
![Page 20: GPs’ decisions on drug therapies by number needed to treat](https://reader036.vdocuments.us/reader036/viewer/2022062518/5681487e550346895db588fd/html5/thumbnails/20.jpg)
(Naimark-D. J Gen Intern Med 1994; 9: 702-707)
Modelling life long treatment:
What NNT should we report?